This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inovio's Ebola Vaccine Positive in Expanded Phase I Study
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001.
Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.
Agenus (AGEN) Sharpens Focus on Drug Development Programs
by Zacks Equity Research
We issued an updated report on Agenus Inc. (AGEN) on Apr 4.
5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now
by Zacks Equity Research
Lily carries a Zacks Rank #2 (Buy).
Bristol-Myers (BMY), Incyte to Advance Clinical Program
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.
Kite Pharma Completes Filing for CAR-T Therapy with FDA
by Zacks Equity Research
Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.
Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma
by Zacks Equity Research
Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).
Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval
by Zacks Equity Research
Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.
Merck Closes Acquisition of Controlling Stake in Vallee S.A
by Zacks Equity Research
Merck & Co., Inc. (MRK) has completed the previously announced acquisition of a controlling stake in Vallee S.A., a leading privately held producer of animal health products in Brazil.
Why Biotech Stock Gilead (GILD) Could Be a Value Trap
by Arpita Dutt
Gilead's (GILD) valuation looks compelling but is the company really poised for
Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication
by Zacks Equity Research
Merck & Co., Inc (MRK) announced that it has received FDA approval for Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.
Immune Design (IMDZ) Q4 Loss In Line; Sales Beat Estimates
by Zacks Equity Research
Immune Design Corp.(IMDZ) reported fourth-quarter 2016 loss of 57 cents per share, in line with Zacks Consensus Estimate but narrower than the year-ago loss of 60 cents.
Stock Market Roundup, March 7: SNAP Falls Again, Drug Stocks Dip
by Ryan McQueeney
Stocks opened in the red and were down slightly throughout the day on Tuesday. The healthcare sector witnessed some volatility after the release of the Republican plan to replace Obamacare and shares of Snap Inc. fell another 11% just days after its highly-anticipated IPO.
Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices
by Parth Panchal
A President Donald Trump tweet promising to increase competition and decrease prices in the drug industry sent pharmaceutical stocks falling on Tuesday.
Why Is Merck (MRK) Up 3.7% Since the Last Earnings Report?
by Zacks Equity Research
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
5 FDA Decisions to Watch Out for in Mar 2017
by Arpita Dutt
Companies like Merck (MRK) are awaiting key FDA decisions this month.
What's in Store for Immune Design (IMDZ) in Q4 Earnings?
by Zacks Equity Research
Immune Design Corp (IMDZ) is scheduled to report fourth-quarter 2016 results after the market closes on Mar 7.
Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
by Zacks Equity Research
Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.
M&As, Pipeline Catalysts to Drive Pharma Sector
by Arpita Dutt
The sector's fundamentals remain strong -- innovation, mergers and acquisitions (M&As), product approvals and positive data flow should act as catalysts.
Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.
Pharma Industry Outlook - February/March 2017
by Arpita Dutt
The sector is showing signs of recovery with the NYSE ARCA Pharmaceutical Index gaining 5.1% while the NASDAQ Biotechnology Index is up 7.3%.
Bristol Myers' Future Unsure as Carl Icahn Takes Stake
by Joseph Lu
Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?
Can Carl Icahn Save Bristol Myers Squibb?
by Joseph Lu
Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.